US Medtech Urges Caution To Growing Push For 'Real-World' Device Evaluation System
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration is stepping up efforts to develop and launch a new 'national evaluation system' for medical devices that relies on shared-access registries, claims data, health records and other electronic data, but industry advocates are cautioning against moving too fast. Companies worry about unintended consequences and say more details are needed on how the broad-based initiative to expand availability of "real-world" evidence for devices will impact the medtech innovation cycle.
You may also be interested in...
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.
MoCRA’s Adulteration Ambiguity And FDA’s New Cosmetic Recall Authority: Attorney Weighs In
The US FDA should use guidance or rulemaking to clarify MoCRA provisions related to adulteration, Amin Wasserman Gurnani attorney Angela Diesch suggested at the Independent Beauty Association’s Cosmetics Convergence Spring Symposium. Attendees also sought her take on whether the agency’s new recall authority is likely to spell an increase in cosmetic product recalls.
Medtronic Launches Remote Live-Stream Surgery, New AI Capabilities
Medtronic will launch a new feature that allows for live streaming of surgical procedures in more than 20 countries and the addition of 14 AI-driven algorithms to enhance surgical workflow.